Skip to main content

Table 5 Cox Regression analysis to determine factors associated with LTFU, Tshepang Pharmacovigilance cohort, 2004-2012

From: Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004–2012: a cohort study

Characteristic

 

Univariate analysis

Multivariate Analysis

  

HR

95 % CI

P value

aHR

95 % CI

P value

Age at ART

≥ 45

Ref*

  

Ref*

  

Initiation

≥ 30 and < 45

0.77

0.50 - 1.19

0.240

0.71

0.37 - 1.37

0.310

 

< 30

0.94

0.59 - 1.51

0.810

0.58

0.28 - 1.21

0.144

Partner status

Present

Ref*

  

Ref*

  
 

Absent

1.75

1.08 - 2.84

0.024

2.88

1.19 - 6.97

0.019

Employment

Employed

Ref*

  

Ref*

  

Status

Self employed

7.18

1.69 - 30.54

0.008

13.92

2.81 - 69.06

0.001

 

Unemployed

1.57

1.01 - 2.44

0.045

1.75

0.86 - 3.56

0.123

Adverse events

No

Ref*

  

Ref*

  
 

Yes

0.49

0.34 - 0.70

<0.001

0.61

0.38 - 0.99

0.044

Baseline CD4

CD4 ≤ 200

Ref*

  

Ref*

  

Count

CD4 > 200

2.47

1.42 - 4.31

0.001

3.81

1.85 - 7.85

< 0.001

First VL level

Undetectable VL

Ref*

  

Ref*

  

after ART

Detectable VL

1.81

1.21 - 2.72

0.004

1.00

0.58 - 1.73

0.998

Last known CD4

CD4 ≤ 200

Ref*

  

Ref*

  

Count

CD4 > 200

0.42

0.29 - 0.60

< 0.001

0.88

0.51 - 1.53

0.651

Last known VL

Undetectable VL

Ref*

  

Ref*

  

Level

Detectable VL

3.20

2.20 - 4.67

< 0.001

3.60

1.98 - 6.52

< 0.001

Last known WHO

Stage 1 or 2

Ref*

  

Ref*

  

clinical stage

Stage 3 or4

3.20

2.24 - 4.57

< 0.001

2.00

1.22 - 3.27

0.006

  1. *Ref - Reference category
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us